Allan Wan is a senior associate in the Corporate & Securities practice in Mayer Brown's Hong Kong office.

Allan advises on private equity transactions, mergers and acquisitions and joint ventures. He negotiates, drafts and advises on shareholder agreements, share purchase agreements and joint venture agreements as well as all matters of corporate and commercial law. He was previously seconded to the Corporate & Securities practice in Mayer Brown’s New York office.

Allan speaks fluent English, Mandarin and Cantonese.

Spoken Languages

  • English
  • Mandarin
  • Cantonese


  • Advised BeiGene, Ltd. on the sale of 20.5% of its equity interest to Amgen Inc. by way of issuance of subscription shares for a consideration of US$2.78 billion, together with the in-licensing of clinical-stage drug candidates as part of a broader strategic collaboration.
  • Advised Meitu, Inc. in the acquisition of 57.09% equity interest in a private company operating a recruitment social networking platform in China for a consideration of HK$395 million.
  • Advised BeiGene, Ltd. on a US$2.08 billion registered direct offering to Baker Bros. Advisors LP, Hillhouse Capital Advisors Ltd. and Amgen Inc.
  • Advised AGTech Holdings Limited on the sale of its majority stake to a subsidiary of a Chinese multinational technology company by way of issuance of subscription shares and convertible bonds for a consideration of HK$2.3 billion.


The University of Hong Kong, PCLL

University of Pennsylvania Law School, LLM

The University of Hong Kong, JD

Simon Fraser University, BA


  • Hong Kong
  • New York